Rapamycin reduced malignant markers and aberrant mammary stem cells in surgical specimens.
Researchers examined whether rapamycin could reduce malignant markers and the number of aberrant mammary stem/progenitor cells (MaSCs) in surgical specimens. The study found that rapamycin did reduce both malignant markers and aberrant MaSCs numbers. This was an ex vivo or tissue-based study design.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Dec 5, 2023 · Discovered: Sep 19, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Other
- Sample size
- —
- Duration
- —
- Population
- Surgical specimens (breast tissue)
- Primary outcome
- Reduction in malignant markers and aberrant mammary stem/progenitor cells (MaSCs) number
- Effect size
- —
- Significance
- Not reported
- Journal
- LuZhe Sun
- Published
- Dec 5, 2023
Sources
Primary source
- LuZhe Sun ↗Clinical trial
Source versions
Assessment history
9/24/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.